ARWR ~ This is straight from the website.
Arrowhead and Shire are collaborating to develop and commercialize targeted peptide-drug conjugates (PDCs) using Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and is eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales.
Arrowhead and Shire are collaborating to develop and commercialize targeted peptide-drug conjugates (PDCs) using Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and is eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales.
Peptide Targeting
Arrowhead and Shire are collaborating to develop and commercialize targeted peptide-drug conjugates (PDCs) using Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and is eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales.
IT-101 (now CRLX-101)
Alnylam has received a license from Arrowhead to utilize their Dynamic Polyconjugate (DPC) delivery technology for an RNAi therapeutic product. Alnylam expects to deploy this technology for an undisclosed target in its "Alnylam 5x15" pipeline that is focused on genetically defined targets and diseases. Arrowhead is eligible to receive from Alnylam milestone payments and royalties on sales of product resulting from the license Less
Sentiment: Strong Buy
Exchange Personmarks?
